Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-08-16 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
海通证券股份有限公司关于上海宣泰医药科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the use of idle raised funds by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. for cash management. It includes specifics about the raised funds, their usage, investment purpose, risk analysis, approval procedures, and supervisory opinions. The document references regulatory guidelines and includes a verification opinion from the sponsor institution. It is not a brief announcement but a substantive report on the use of raised funds, specifically focusing on cash management of idle raised funds. This fits the category of Capital/Financing Update (CAP), as it deals with updates on the company's fundraising and capital usage activities, particularly the management of idle raised funds for cash management purposes. The document length (3947 characters) is under 5000 but contains detailed content, not just an announcement of a report. Therefore, it is not a Report Publication Announcement (RPA). It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or other categories. Hence, the best classification is CAP with high confidence.
2024-08-16 Chinese
首次公开发行战略配售限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO) strategic placement. It details the number of shares becoming freely tradable, the dates involved, shareholder commitments, and verification by the sponsoring institution. The document does not contain financial statements or detailed financial analysis but serves as a formal notice about the change in share circulation status. It is not an annual report, earnings release, or management report. It fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share circulation and compliance with listing rules.
2024-08-16 Chinese
关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the board and supervisory approvals, the amount and purpose of the cash management, risk control measures, and opinions from the supervisory board and the sponsoring institution. The document references regulatory approvals and compliance with listing rules but does not contain financial statements or detailed financial results. It is a regulatory announcement about the company's capital management activities related to raised funds, not a full financial report or earnings release. The document length is 3655 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-08-16 Chinese
第二届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the meeting date, attendance, and the approval of a proposal regarding the use of idle raised funds for cash management. The document includes voting results and references compliance with regulatory guidelines. It does not contain financial statements or detailed financial data but is an official announcement of a board/management decision. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or a notice of report publication, so it is not RPA or RNS.
2024-08-16 Chinese
海通证券股份有限公司关于上海宣泰医药股份有限公司首次公开发行部分战略配售限售股上市流通的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Haitong Securities regarding the listing and circulation of restricted shares from the initial public offering (IPO) of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It discusses the details of the restricted shares, their lock-up period, shareholder commitments, and confirms compliance with relevant laws and regulations. The document is not a full financial report, earnings release, or management discussion. It is a formal verification or audit opinion related to share listing and circulation compliance, which fits the category of an Audit Report / Information (AR). The document length is 2173 characters, indicating it is a concise report rather than a brief announcement or notice. Therefore, the best classification is AR with high confidence.
2024-08-16 Chinese
关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase (stock buyback) program by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the number of shares repurchased, the price range, the total amount spent, and compliance with relevant regulations. It does not contain financial statements or detailed financial analysis but is a regulatory disclosure about the company's share repurchase activity. This fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares.
2024-07-31 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.